476 related articles for article (PubMed ID: 37046992)
21. Who Deserves Endoscopic Screening for Esophageal Neoplasia?
Blevins CH; Iyer PG
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):365-378. PubMed ID: 28577762
[TBL] [Abstract][Full Text] [Related]
22. Etiology of Barrett's metaplasia and esophageal adenocarcinoma.
Kim R; Weissfeld JL; Reynolds JC; Kuller LH
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):369-77. PubMed ID: 9149898
[TBL] [Abstract][Full Text] [Related]
23. Barrett's oesophagus: Current controversies.
Amadi C; Gatenby P
World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus.
McManus DT; Olaru A; Meltzer SJ
Cancer Res; 2004 Mar; 64(5):1561-9. PubMed ID: 14996709
[TBL] [Abstract][Full Text] [Related]
25. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
26. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review.
Shaheen N; Ransohoff DF
JAMA; 2002 Apr; 287(15):1972-81. PubMed ID: 11960540
[TBL] [Abstract][Full Text] [Related]
27. A predictive Bayesian network that risk stratifies patients undergoing Barrett's surveillance for personalized risk of developing malignancy.
Bradley A; Sami S; N G H; Macleod A; Prasanth M; Zafar M; Hemadasa N; Neagle G; Rosindell I; Apollos J
PLoS One; 2020; 15(10):e0240620. PubMed ID: 33045017
[TBL] [Abstract][Full Text] [Related]
28. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
[TBL] [Abstract][Full Text] [Related]
29. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.
Sharma P; Katzka DA; Gupta N; Ajani J; Buttar N; Chak A; Corley D; El-Serag H; Falk GW; Fitzgerald R; Goldblum J; Gress F; Ilson DH; Inadomi JM; Kuipers EJ; Lynch JP; McKeon F; Metz D; Pasricha PJ; Pech O; Peek R; Peters JH; Repici A; Seewald S; Shaheen NJ; Souza RF; Spechler SJ; Vennalaganti P; Wang K
Gastroenterology; 2015 Nov; 149(6):1599-606. PubMed ID: 26296479
[TBL] [Abstract][Full Text] [Related]
30. Barrett's esophagus in 2008: an update.
Wood RK; Yang YX
Keio J Med; 2008 Sep; 57(3):132-8. PubMed ID: 18854665
[TBL] [Abstract][Full Text] [Related]
31. [Management of complicated Barrett's esophagus. Observational study carried out in a regional hospital].
Basbous S; Deflandre JJ; Delhougne B; Frère AM; Croës F; Rinken C; Putzeys V; Vijverman A; Pirenne C; Ledouble V; Brixko C; Dresse D; De Roover A; Kotzampassakis N; Demarche M; Fridman V; Deflandre JM
Rev Med Liege; 2022 Mar; 77(3):167-174. PubMed ID: 35258865
[TBL] [Abstract][Full Text] [Related]
32. Barrett's esophagus: What do we need to know?
Mohy-Ud-Din N; Krill TS; Shah AR; Chatila AT; Singh S; Bilal M; Parupudi S
Dis Mon; 2020 Jan; 66(1):100850. PubMed ID: 30808502
[TBL] [Abstract][Full Text] [Related]
33. Categorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework.
Honing J; Fitzgerald RC
Cancer Prev Res (Phila); 2023 Jun; 16(6):313-320. PubMed ID: 37259801
[TBL] [Abstract][Full Text] [Related]
34. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
35. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Gatenby P; Caygill C; Wall C; Bhatacharjee S; Ramus J; Watson A; Winslet M
World J Gastroenterol; 2014 Jul; 20(28):9611-7. PubMed ID: 25071359
[TBL] [Abstract][Full Text] [Related]
36. Barrett's esophagus.
Phillips WA; Lord RV; Nancarrow DJ; Watson DI; Whiteman DC
J Gastroenterol Hepatol; 2011 Apr; 26(4):639-48. PubMed ID: 21166712
[TBL] [Abstract][Full Text] [Related]
37. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
O'Connor JB; Falk GW; Richter JE
Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
[TBL] [Abstract][Full Text] [Related]
38. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
39. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
[TBL] [Abstract][Full Text] [Related]
40. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
